BARINTHUS BIOTHERAPEUTICS PL (BRNS) Stock News
NASDAQ:BRNS - Nasdaq - US91864C1071 - ADR - Currency: USD
BRNS Latest News, Press Relases and Analysis
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially...
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic...
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Barinthus Biotherapeutics (NASDAQ:BRNS) just reported results for the second qu...
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today...
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Mentions: ABUS
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results...
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer ...
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease...
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
BRNS stock results show that Barinthus Biotherapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results...
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections...
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024....
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
Mentions: ABUS
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024
BRNS stock results show that Barinthus Biotherapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments...
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.